NextPharma Senior Appointments
London – 22 July 2005
NextPharma the leading European provider of drug development and manufacturing outsourcing services to the pharmaceutical industry has made the following recent appointments to its senior management team:
Karen Stoddart has joined NextPharma as SVP Quality. Ms. Stoddart is a qualified pharmacist and has significant experience in Quality Assurance, Manufacturing and Development gained at Glaxo, Chiroscience and Mallinckrodt. She has worked in the US and Europe and has experience of global regulatory compliance in Japan. Most recently she led the Quality Strategy function at UCB Celltech.
Monika Osterwald has been appointed as VP Supply Chain Management.
Mrs. Osterwald is a qualified pharmacist and joined the NextPharma group in 1990. In addition to her extensive logistics experience she has also established and led Sales and Marketing for the German group. In addition to her new role Mrs. Osterwald will continue to be responsible for the Group Purchasing function.
Maureen Roberts has joined NextPharma as VP HR and Communications. Mrs. Roberts qualified as a member of the Chartered Institute of Personnel and Development in 1985 and has gained considerable experience from a variety of HR and Communications roles in the public and private sectors, including the National Health Service and the Pharmaceutical and Finance industries. Most recently she led global Internal Communications for Amersham Health.
All three appointees will report directly to Bill Wedlake, CEO, NextPharma Technologies, who commented as follows:
“These appointments are a further step in positioning NextPharma to serve our customers’ increasingly wide ranging and complex requirements for outsourcing services better. We are totally focused on providing the highest quality services with an emphasis on technical solutions and working in partnership with our customers. It is our objective to ensure that NextPharma remains in a position to offer timely, competitive, healthcare outsourcing solutions of the highest quality as the pharma and biotech markets continue to develop”
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing biopharma drug development, clinical trials, packaging and manufacturing outsourcing sector. It has eight manufacturing facilities based in Germany, Belgium and France employing over 1,100 people and has a customer base which includes many of the worlds leading pharmaceutical companies. NextPharma’s principle shareholder is Credit Suisse First Boston Private Equity.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.